Why the Avita (ASX:AVH) share price is charging higher today

The Avita Therapeutics Inc (ASX:AVH) share price is charging higher on Monday. Here's why the Avita share price is on the rise…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Avita Therapeutics Inc (ASX: AVH) share price has started the week in a positive fashion.

The regenerative medicine company's shares are up over 3% to $7.43 in afternoon trade.

Why is the Avita share price charging higher?

The catalyst for today's gain has been the release of an update on its pivotal study assessing the use of the RECELL System to treat stable vitiligo.

The RECELL System is currently used to prepare Spray-On Skin Cells using a small amount of a patient's own skin. This provides a new way to treat severe burns, while significantly reducing the amount of donor skin required.

Avita is aiming to extend its use to treat other unmet medical needs and took a step forward to doing so today. This morning the company announced the initiation of the pivotal vitiligo study following the enrolment of the first patient at the Miami Dermatology and Laser Institute in Florida, United States.

This study will evaluate the safety and effectiveness of the RECELL System to repigment skin in patients who have vitiligo that has been stable for at least one year.

Vitiligo is an autoimmune disease that attacks the epidermis layer of skin. This results in loss of colour or pigmentation. This serious skin condition affects up to 2% of the global population, including an estimated 6.5 million Americans.

There is currently no cure for vitiligo, nor a universally accepted method for limiting the spread of the disease. And while many treatments are being used for its management, they are often temporary with a high rate of recurrence.

A milestone.

The company's CEO, Dr Mike Perry, believes the initiation of the vitiligo clinical study is a milestone in advancing its pipeline to leverage the utility and full potential of the innovative RECELL technology platform to address unmet medical needs in dermatological applications.

Dr Perry commented: "Globally, there have been several published case series and pilot randomized clinical trials reporting positive results with the use of RECELL for treating patients with stable vitiligo and repigmenting depigmented skin lesions. We are pleased to initiate this pivotal study as a next step toward offering a treatment option for the millions of Americans who live with vitiligo."

The Medical Director of Miami Dermatology and Laser Institute, Jill Waibel, MD, spoke positively about the RECELL System's potential.

Waibel said: "While often considered a cosmetic issue, vitiligo can greatly impact the quality of life of those living with the disease, and treatment options are limited. We look forward to assessing the safety and efficacy of the RECELL System in restoring skin colour in stable vitiligo lesions and potentially offering those who live with vitiligo hope with a new, easy in-office treatment."

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX biotech shares rocketing more than 40% on big news

These two ASX healthcare companies have exciting news for investors today.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Aurora Labs, Coronado Global, Latin Resources, and Newmont shares are rising

These shares are having a better day than most. But why?

Read more »

A woman is excited as she reads the latest rumour on her phone.
Share Gainers

Why Catalyst Metals, Ora Banda, Spartan Resources, and TechnologyOne shares are rising today

These shares are overcoming the market weakness and pushing higher. But why?

Read more »

Lab worker puts hands in the air and dances around
Healthcare Shares

Guess which ASX healthcare stock just rocketed 46% on major news!

Investors are sending this ASX healthcare stock flying higher on Wednesday. But why?

Read more »

A man sees some good news on his phone and gives a little cheer.
Share Gainers

Why Arafura, Dropsuite, Spartan Resources, and Universal Store shares are pushing higher

These shares are having a strong session on Tuesday. But why?

Read more »

Man on a laptop thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a Garfield-eque start to the trading week this Monday.

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Healthcare Shares

If you invested $5,000 in this ASX pharmaceuticals stock a year ago, you'd have $34,711 now!

Just how lucky have investors been with this stock?

Read more »

A boy stands firm on a rocky cliff holding a rocket in each hand and looking up toward the sky, anticipating flying into space.
Share Gainers

Why these 2 ASX 200 shares are surging amid today's market meltdown

Investors are bidding up these two ASX 200 shares despite the wider market meltdown. But why?

Read more »